Rhea-AI Summary
Jazz Pharmaceuticals has secured exclusive rights to develop and commercialize DSP-0187 in the U.S., Europe, and other regions through a licensing agreement with Sumitomo Pharma. The agreement includes a $50 million upfront payment and up to $1.09 billion in milestone payments. Jazz aims to expedite the development of DSP-0187, a novel oral orexin-2 receptor agonist for treating narcolepsy and other sleep disorders. This collaboration aligns with Jazz's commitment to innovation in sleep medicine, leveraging its expertise in delivering therapies that enhance patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of Sumitomo Pharma (SMDPY)?
Sumitomo Pharma (SMDPY) last closed at $12.08.
What is the market cap of Sumitomo Pharma (SMDPY)?
The market cap of Sumitomo Pharma (SMDPY) is approximately $5.4B.